Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × ipatasertib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Prostatic Neoplasms 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Oropharyngeal Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 2 atezolizumab 2 zenocutuzumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 entrectinib 1 cobimetinib 1 alectinib 1 Whole Genome Sequencing 1 Vemurafenib 1 Transurethral Resection of Prostate 1 Specimen Handling 1 Sequence Analysis, RNA 1 Radiosurgery 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 HhAntag691 1 Genetic Testing 1 Genetic Profile 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Erlotinib Hydrochloride 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡